R
2.13
0.05 (2.40%)
| Previous Close | 2.08 |
| Open | 2.14 |
| Volume | 16,266 |
| Avg. Volume (3M) | 41,055 |
| Market Cap | 102,246,392 |
| 52 Weeks Range |
| Operating Margin (TTM) | -1,146.92% |
| Diluted EPS (TTM) | -0.610 |
| Quarterly Revenue Growth (YOY) | -26.10% |
| Current Ratio (MRQ) | 0.420 |
| Operating Cash Flow (TTM) | -30.92 M |
| Levered Free Cash Flow (TTM) | -17.07 M |
| Return on Assets (TTM) | -85.68% |
| Return on Equity (TTM) | -1,073.18% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Mixed | Bearish |
| Health Information Services (Global) | Mixed | Bearish | |
| Stock | Renalytix plc | Mixed | Mixed |
AIStockmoo Score
0.0
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | NA |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | 0.00 |
|
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Value |
| % Held by Insiders | 4.51% |
| % Held by Institutions | 4.14% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |